Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07384897 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease

Study acronym: IMMUNOPUMON2
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD). The investigators are studying how these immune cells can sometimes help the body defend itself, but in other cases may contribute to cancer growth or long-term lung inflammation. Although recent treatments like immunotherapy have improved cancer care, only a small proportion of patients currently benefit from these therapies. One goal of this research is to understand why some patients do not respond or develop resistance to treatment. The knowledge gained from this study may help researchers develop more effective and personalized treatments for people with lung diseases in the future.
Trial Details
NCT Number NCT07384897
Lead Sponsor Université Catholique de Louvain
Conditions
(from sponsor)		 Lung Cancer (Diagnosis), Sarcoidosis, Chronic Obstructive Pulmonary Disease, Immunotherapy Resistance, Immune Dysregulation
Related terms Carcinoma, Non-Small-Cell Lung, Disease, Inflammation, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive, Sarcoidosis
Enrollment 425 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov